Skip to main content

ADVERTISEMENT

niacin

Original Contribution
11/25/2015

Andres Guerra, BS;  Bavana V. Rangan, BDS, MPH;  Ameka Coleman, MS;  Hao Xu, PhD;  Anna Kotsia, MD;  Georgios Christopoulos, MD;  Alan Sosa, BA;  Howard Chao, BS;  Henry Han, BS;  Guthbudeen Abdurrahim, MD;  Michele Roesle, RN, BSN;  James A. de Lemos, MD;  Darren K. McGuire, MD, MHSc;  Milton Packer, MD;  Subhash Banerjee, MD;  Emmanouil S. Brilakis, MD, PhD

Andres Guerra, BS;  Bavana V. Rangan,...
We sought to evaluate the impact of extended-release niacin on carotid intima media thickness (CIMT), endothelial function, and endothelial progenitor cell (EPC) mobilization. 
We sought to evaluate the impact of extended-release niacin on carotid intima media thickness (CIMT), endothelial function, and endothelial progenitor cell (EPC) mobilization. 
We sought to evaluate the impact...
11/25/2015
Journal of Invasive Cardiology
Original Contribution
10/01/2015

Anna P. Kotsia, MD1;  Bavana V. Rangan, BDS, MPH1;  Georgios Christopoulos, MD1;  Ameka Coleman, BS1;  Michele Roesle, RN, BSN1;  Daisha Cipher, PhD2;  James A. de Lemos, MD1;  Darren K. McGuire, MD, MHSc1;  Milton Packer, MD1;  Subhash Banerjee, MD1;  Emmanouil S. Brilakis, MD, PhD1

Anna P. Kotsia, MD1;  Bavana V. Ranga...
Intermediate SVG lesions have high rates of progression. The purpose of this study was to examine the impact of extended-release niacin (ER-niacin) vs. placebo on intermediate saphenous vein graft (SVG) lesions.
Intermediate SVG lesions have high rates of progression. The purpose of this study was to examine the impact of extended-release niacin (ER-niacin) vs. placebo on intermediate saphenous vein graft (SVG) lesions.
Intermediate SVG lesions have...
10/01/2015
Journal of Invasive Cardiology